Metagenomi Therapeutics, Inc (MGX) Fair Value & Analysis
Healthcare · US · Market cap $45.2M
Metagenomi Therapeutics, Inc
MGX · US
Fair value as of: Jun 25, 2026
From 1 valuation models · updated 4 days ago
Fair value updated Jun 25, 2026 — revised from $18.96 to $2.74 (−85.5%) since Jun 24, 2026. Share price −11.8% over the past month.
Price vs Fair Value (12 months)
12‑month range $1.18 – $3.46 · fair‑value band $1.81 – $3.42 · the $1.24 price screens below the $2.74 fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Metagenomi Therapeutics, Inc (MGX) currently trades at $1.24, while our model-based Fair Value estimate is $2.74 — implying the stock looks roughly 121.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at $22.3M. Revenue declined 69.8% year over year. It earns a return on equity of -49.0%. The balance sheet holds a net cash position of $1.1M. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Metagenomi Therapeutics, Inc reported revenue of $25.2M in FY2025 versus $243K in FY2021, a compound +219.1%/yr. Reported net income was −$87.9M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Metagenomi Therapeutics, Inc (MGX) undervalued?
What is the fair value of MGX?
What is the quality score of MGX?
What is the revenue of Metagenomi Therapeutics, Inc (MGX)?
What is the net profit margin of MGX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.